新京报讯(记者王卡拉)6月16日,复星医药与Teva Pharmaceutical Industries(“梯瓦”)宣布,双方通过各自的子公司,就在研药物抗PD1-IL2 ATTENUKINE疗法TEV-56278的开发达成战略合作。梯瓦自主研发的ATTENUKINE技术,通过全新作用机制,有望针对多项肿瘤免疫治疗适应症实现高效低毒的治疗效果。 根据协议,为加速临床数据开发,复星医药将获得TEV...
Source Link新京报讯(记者王卡拉)6月16日,复星医药与Teva Pharmaceutical Industries(“梯瓦”)宣布,双方通过各自的子公司,就在研药物抗PD1-IL2 ATTENUKINE疗法TEV-56278的开发达成战略合作。梯瓦自主研发的ATTENUKINE技术,通过全新作用机制,有望针对多项肿瘤免疫治疗适应症实现高效低毒的治疗效果。 根据协议,为加速临床数据开发,复星医药将获得TEV...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.